- Salvadori, Nicolas;
- Fan, Bo;
- Teeyasoontranon, Waralee;
- Ngo-Giang-Huong, Nicole;
- Phanomcheong, Siriluk;
- Luvira, Anita;
- Puangsombat, Achara;
- Suwannarat, Arunrat;
- Srirompotong, Ussanee;
- Putiyanun, Chaiwat;
- Cressey, Tim;
- Decker, Luc;
- Khamduang, Woottichai;
- Harrison, Linda;
- Tierney, Camlin;
- Shepherd, John;
- Kourtis, Athena;
- Bulterys, Marc;
- Siberry, George;
- Jourdain, Gonzague
In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.
